Systemische Therapie des metastasierten Nierenzellkarzinoms

Translated title of the contribution: Systemic therapy for metastatic renal cell carcinoma

M. W. Kramer, S. Steffens, C. Von Klot, A. S. Merseburger, M. A. Kuczyk*

*Corresponding author for this work
2 Citations (Scopus)


A better understanding of molecular biological mechanisms involved in the pathogenesis or, respectively, prognosis of renal cell carcinoma has recently led to a fundamental change in those therapeutic options that are especially effective after systemic disemination. In this context, cytokine-based therapeutic concepts have been replaced by the so-called targeted therapeutic agents that include, above all, tyrosine kinase (TK) and mTOR inhibitors. The present contribution is intended to reflect the current state of the art in the systemic therapy for renal cell carcinoma in first- and second-line use. In addition, the increasing relevance of sequential therapy under consideration of possible side effects is discussed.

Translated title of the contributionSystemic therapy for metastatic renal cell carcinoma
Original languageGerman
JournalAktuelle Urologie
Issue number4
Pages (from-to)265-268
Number of pages4
Publication statusPublished - 2012

Research Areas and Centers

  • Research Area: Luebeck Integrated Oncology Network (LION)


Dive into the research topics of 'Systemic therapy for metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this